EMA CHMP supports CStone’s sugemalimab for metastatic NSCLC

03 Jun 2024
www.pharmaceutical-technology.com
Drug ApprovalPhase 3Clinical ResultNDA
EMA CHMP supports CStone’s sugemalimab for metastatic NSCLC
Preview
Source: Pharmaceutical Technology
CStone has already secured sugemalimab’s approval in China for five cancer indications. Credit: Marko Aliaksandr/Shutterstock.com.
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of CStone’s sugemalimab, an anti-PD-L1 monoclonal antibody (mAb), for first-line treatment of metastatic non-small cell lung cancer (NSCLC).
Recommended Buyer's Guides
EMA CHMP supports CStone’s sugemalimab for metastatic NSCLC
Preview
Source: Pharmaceutical Technology
Buyer's Guide
Leading Guide to Packaging Materials, Containers and Containment Services for the Pharmaceutical Industry
EMA CHMP supports CStone’s sugemalimab for metastatic NSCLC
Preview
Source: Pharmaceutical Technology
Buyer's Guide
Leading Guide to Clinical Packaging Companies in contract Manufacturing for the Pharmaceutical Industry
CStone’s sugemalimab has been recommended in combination with chemotherapy as a first-line treatment for NSCLC.
The endorsement could mark the first anti-PD-L1 monoclonal antibody approved for both squamous and non-squamous NSCLC, irrespective of PD-L1 expression, in Europe.
The CHMP’s positive opinion is based on the GEMSTONE-302 study, a multi-centre, randomised, double-blind, Phase 3 clinical trial showing significant improvements in progression-free survival (PFS) and overall survival (OS) when sugemalimab is combined with chemotherapy in previously untreated stage IV NSCLC patients.
CStone CEO, executive director and research and development president Dr Jason Yang stated: “The positive opinion from EMA CHMP normally indicates an upcoming approval for market authorisation by the European Commission, marking a significant milestone not only for sugemalimab but also for CStone and the entire pharmaceutical industry in China.
See Also:Compound medication pharmacies and companies
EMA CHMP supports CStone’s sugemalimab for metastatic NSCLC
Preview
Source: Pharmaceutical Technology
Dupixent gets closer to EU approval as the FDA delays its decision on COPD
EMA CHMP supports CStone’s sugemalimab for metastatic NSCLC
Preview
Source: Pharmaceutical Technology
“The CHMP recommendation brings us closer to delivering this innovative treatment to European patients with lung cancer, and it also highlights a major milestone in CStone’s global strategy.”
CStone has already secured approval for sugemalimab in China for five cancer indications.
In China, the National Medical Products Administration (NMPA) has approved sugemalimab for stage III and IV NSCLC, extranodal NK/T-cell lymphoma, oesophageal squamous cell carcinoma and gastric cancer.
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) is undertaking a marketing authorisation application review for sugemalimab for metastatic NSCLC.
CStone is in discussions with the EMA, the UK Medicines and Healthcare products Regulatory Agency, and the US Food and Drug Administration for additional indications.
It is looking at development and commercialisation partnerships in countries and regions worldwide.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.